



IP GROUP'S PURPOSE IS TO EVOLVE **GREAT IDEAS INTO WORLD-CHANGING BUSINESSES** THAT ACHIEVE A POSITIVE IMPACT ON THE ENVIRONMENT AND SOCIETY AS WELL AS A FINANCIAL RETURN.

Sustainability has always been at the heart of IP Group. Through the businesses that we back and build, we aim to address some of the world's most pressing challenges in areas such as disease prevention and mitigation, the transition to a less carbon intense energy world and productivity improvement. Our approach therefore considers environmental, social and governance ("ESG") factors and their impact.

Our team is passionate about this endeavour and has spent many years finessing its approach to identifying attractive intellectual property, nurturing and building businesses around that IP and then providing capital and support along the journey from 'cradle to maturity'. Through collaborations and established partner relationships with leading research institutions in the UK, the US and Australasia, the Group seeks to access and commercialise a wealth of scientific research.

WE SUPPORT



FTSE4Good

## OUR STRATEGIC AIMS



To **create** and maintain a pipeline of compelling intellectual property-based opportunities



To **develop** and support these opportunities into a diversified portfolio of robust businesses



To **deliver** attractive financial returns on our assets and third party funds

## 20 YEARS OF IMPACT INVESTING SUPPORTING WORLD-CHANGING BUSINESSES

Three unicorns created to date



Pioneering the world's most patient-centered digital clinic for back and joint pain



Enabling DNA analysis by anyone anywhere



Steel fuel cells for cheaper, cleaner, distributed power generation\*



Reprogramming metabolism to treat autoimmune and inflammatory conditions

### FEATURE SPACE

Adaptive Behavioural Analytics for real time fraud detection



Liquid biopsy for cancer care

\*Exited Ceres Power in 2020 at seven times cost

## IP GROUP PLC LEADERSHIP



**Sir Douglas Flint**  
Chairman

Former Group Chairman of HSBC Holdings plc, former Group Finance Director of HSBC. Former partner of KPMG. Former Non-Executive Director of BP plc.

Chairman of the Corporate Board of Cancer Research UK, Trustee of the Royal Marsden Cancer Charity.

**Alan Aubrey**  
Chief Executive Officer


Corporate finance background (partner KPMG)

Deep expertise of building technology businesses


Co-founder Techtran Group Ltd; bought by IP Group plc




# IP GROUP AT A GLANCE



## Fair value by business unit



## Fair value by focus



# SUPPORTING SUSTAINABLE DEVELOPMENT

THEMATIC FOCUS	PORTFOLIO COMPANY	SDG TARGET	SUSTAINABLE DEVELOPMENT GOAL
Deep Tech  DATA ANALYTICS CYBER DEFENCE IT TO IMPROVE EFFICIENCY	AMSL Innovations Aqdot Featurespace GarrisonTechnology Ultraleap Holdings Ltd C-Capture Mixergy Oxbotica Oxford Sciences Innovation plc Uniformity Labs WaveOptics Import.IO Chromosol Ltd Yoyo Wallet Ltd	11.2 Affordable and sustainable transport systems 11.3 Inclusive & sustainable urbanisation 11.6 Reduce the environmental impact of cities 9.1 Develop sustainable, resilient & inclusive infrastructures 9.4 Upgrade all industries and infrastructures for sustainability 9.5 Enhance research and upgrade industrial technologies 9.C Universal access to ICT 8.2 Achieve higher levels of productivity of economies through diversification, technological upgrading and innovation	11 SUSTAINABLE CITIES AND COMMUNITIES  9 INDUSTRY, INNOVATION AND INFRASTRUCTURE  8 DECENT WORK AND ECONOMIC GROWTH
	Cleantech  RENEWABLE ENERGY SUSTAINABLE TRANSPORT ENERGY TRANSITION	Azuri Technologies Bramble Energy C-Capture First Light Fusion Oxbotica Oxford Nanopore Technologies Mixergy RFC Power	7.1 Universal access to modern energy 7.2 Increase global percentage of renewable energy 7.3 Double energy efficiency 7.A Promote R&D and investment into cleantech 7.B Expand & upgrade energy services in developing countries 13.2 Integrate climate change measures into policies & planning 13.3 Build knowledge & capacity to meet climate change
Life Sciences  DIAGNOSTICS THERAPEUTICS ONCOLOGY DIGITAL HEALTH	Artios Pharma Centessa (Apcintex) Crescendo Biologics Diurnal Group Enterprise Therapeutics Hinge Health Ieso Digital Health Inivata Istesso Microbiotica Mission Therapeutics MOBILion Navenio Oxford Nanopore Technologies PsiOxus Therapeutics Pulmocide Ltd	3.3 By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases and promote mental health and well being 3.D Strengthen the capacity for early warning, risk reduction and management of national and global health risks.	3 GOOD HEALTH AND WELL-BEING

[www.ipgroupplc.com](http://www.ipgroupplc.com)  
Stock code (LSE): IPO

Numbers as at 31 December 2020